JP2012131790A - ベンダムスチンアルキルエステル、ベンダムスチン、およびそれらの誘導体の製造のためのプロセス - Google Patents
ベンダムスチンアルキルエステル、ベンダムスチン、およびそれらの誘導体の製造のためのプロセス Download PDFInfo
- Publication number
- JP2012131790A JP2012131790A JP2011273992A JP2011273992A JP2012131790A JP 2012131790 A JP2012131790 A JP 2012131790A JP 2011273992 A JP2011273992 A JP 2011273992A JP 2011273992 A JP2011273992 A JP 2011273992A JP 2012131790 A JP2012131790 A JP 2012131790A
- Authority
- JP
- Japan
- Prior art keywords
- formula
- radical
- compound represented
- alkyl radical
- bendamustine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 48
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 16
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 title abstract description 20
- 229960002707 bendamustine Drugs 0.000 title abstract description 20
- 150000001875 compounds Chemical class 0.000 claims abstract description 82
- 238000006243 chemical reaction Methods 0.000 claims abstract description 18
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 claims abstract description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims abstract description 8
- -1 halogen radical Chemical group 0.000 claims description 88
- 150000003254 radicals Chemical class 0.000 claims description 43
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 27
- 150000003839 salts Chemical class 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 14
- 239000002904 solvent Substances 0.000 claims description 12
- 229910052736 halogen Inorganic materials 0.000 claims description 10
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 9
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical compound [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 claims description 8
- OCBFFGCSTGGPSQ-UHFFFAOYSA-N [CH2]CC Chemical compound [CH2]CC OCBFFGCSTGGPSQ-UHFFFAOYSA-N 0.000 claims description 7
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical compound C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 claims description 7
- WPWHSFAFEBZWBB-UHFFFAOYSA-N 1-butyl radical Chemical compound [CH2]CCC WPWHSFAFEBZWBB-UHFFFAOYSA-N 0.000 claims description 6
- 238000010931 ester hydrolysis Methods 0.000 claims description 5
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 3
- 239000000010 aprotic solvent Substances 0.000 claims description 2
- 150000001805 chlorine compounds Chemical group 0.000 claims 1
- 239000002253 acid Substances 0.000 abstract description 13
- 150000002148 esters Chemical class 0.000 abstract description 13
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract description 6
- 239000007858 starting material Substances 0.000 abstract description 3
- 125000005843 halogen group Chemical group 0.000 abstract description 2
- 238000006467 substitution reaction Methods 0.000 abstract description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 description 40
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 30
- 239000000243 solution Substances 0.000 description 23
- 239000007795 chemical reaction product Substances 0.000 description 18
- 239000011541 reaction mixture Substances 0.000 description 18
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 16
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
- GVLZDNWNOBSNEN-UHFFFAOYSA-N ethyl 4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoate Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(=O)OCC)=NC2=C1 GVLZDNWNOBSNEN-UHFFFAOYSA-N 0.000 description 13
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 239000012074 organic phase Substances 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 239000008346 aqueous phase Substances 0.000 description 6
- SJYOJVBTSZGDQH-UHFFFAOYSA-N ethyl 4-[5-[bis(2-hydroxyethyl)amino]-1-methylbenzimidazol-2-yl]butanoate Chemical compound OCCN(CCO)C1=CC=C2N(C)C(CCCC(=O)OCC)=NC2=C1 SJYOJVBTSZGDQH-UHFFFAOYSA-N 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- 229910052801 chlorine Inorganic materials 0.000 description 5
- 238000004821 distillation Methods 0.000 description 5
- 230000008030 elimination Effects 0.000 description 5
- 238000003379 elimination reaction Methods 0.000 description 5
- 239000012458 free base Substances 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 150000001450 anions Chemical class 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- OBNCKNCVKJNDBV-UHFFFAOYSA-N ethyl butyrate Chemical compound CCCC(=O)OCC OBNCKNCVKJNDBV-UHFFFAOYSA-N 0.000 description 4
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 3
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 3
- 0 Cc1cc(N(CC*)CC*)ccc1* Chemical compound Cc1cc(N(CC*)CC*)ccc1* 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- XHMWSXLDNNNEPC-UHFFFAOYSA-N ethyl 4-[4-[bis(2-chloroethyl)amino]phenyl]butanoate Chemical compound CCOC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 XHMWSXLDNNNEPC-UHFFFAOYSA-N 0.000 description 2
- 150000004820 halides Chemical group 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- NAQNVOSSGCIIDH-UHFFFAOYSA-N 4-[4-[bis(2-chloroethyl)amino]phenyl]butanoic acid;hydrochloride Chemical compound [Cl-].OC(=O)CCCC1=CC=C([NH+](CCCl)CCCl)C=C1 NAQNVOSSGCIIDH-UHFFFAOYSA-N 0.000 description 1
- YTKUWDBFDASYHO-UHFFFAOYSA-M 4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoate Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC([O-])=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-M 0.000 description 1
- XQMDIDKYVZPCNV-UHFFFAOYSA-N 4-[5-[bis(2-hydroxyethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid Chemical compound OCCN(CCO)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 XQMDIDKYVZPCNV-UHFFFAOYSA-N 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- BWTJUHWTUKNKLL-UHFFFAOYSA-N ethyl 4-[4-[bis(2-hydroxyethyl)amino]phenyl]butanoate Chemical compound CCOC(=O)CCCC1=CC=C(N(CCO)CCO)C=C1 BWTJUHWTUKNKLL-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 description 1
- 150000007976 iminium ions Chemical class 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- IZDROVVXIHRYMH-UHFFFAOYSA-N methanesulfonic anhydride Chemical compound CS(=O)(=O)OS(C)(=O)=O IZDROVVXIHRYMH-UHFFFAOYSA-N 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 229910052756 noble gas Inorganic materials 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 125000002827 triflate group Chemical group FC(S(=O)(=O)O*)(F)F 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
- C07C209/44—Preparation of compounds containing amino groups bound to a carbon skeleton by reduction of carboxylic acids or esters thereof in presence of ammonia or amines, or by reduction of nitriles, carboxylic acid amides, imines or imino-ethers
- C07C209/46—Preparation of compounds containing amino groups bound to a carbon skeleton by reduction of carboxylic acids or esters thereof in presence of ammonia or amines, or by reduction of nitriles, carboxylic acid amides, imines or imino-ethers by reduction of carboxylic acids or esters thereof in presence of ammonia or amines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/12—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B41/00—Formation or introduction of functional groups containing oxygen
- C07B41/08—Formation or introduction of functional groups containing oxygen of carboxyl groups or salts, halides or anhydrides thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
- C07C209/82—Purification; Separation; Stabilisation; Use of additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/43—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C211/44—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring
- C07C211/45—Monoamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
- C07C227/16—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions not involving the amino or carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
- C07C227/18—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions involving amino or carboxyl groups, e.g. hydrolysis of esters or amides, by formation of halides, salts or esters
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
【解決手段】本発明に係る方法を用いて、これらの化合物の製造は、再現性よく高収率で可能である。この目的のために、ヒドロキシル基含有エステルが、出発物質として使用され、このヒドロキシル基含有エステルのヒドロキシル基はハロゲン基によって簡単に置換される。この置換は、(i)塩化オキサリルおよび(ii)ジアルキルホルムアミド、ジアルキルアセトアミドまたはジメチルスルホキシドの存在下で可能である。その後の反応で、得られたエステルは、加水分解され、酸を形成することができる。
【選択図】なし
Description
26.7gの塩化オキサリル(1.6当量)を、279mlのジクロロメタンに溶解し、1℃に冷却した。1℃で、17mlのジメチルホルムアミド(DMF)および50mlの乾燥ジクロロメタンの混合物をゆっくり加えた。115mlのジクロロメタン中の23gの4−(5−(ビス−(2−ヒドロキシエチル)−アミノ)−1−メチル−1H−ベンゾ[d]イミダゾール−2−イル)ブタン酸エチルの溶液を、得られた反応混合物に加えた。この反応混合物を、還流しながら8時間撹拌し(45℃のジャケット温度)、冷却し、次いで50mlの超純水と混合した。25% K2CO3溶液の添加によって、pH値をpH 8〜9.5に調整した。強力で十分な混合後、有機相を分離し、水相を、さらなる83mlのジクロロメタンで抽出した。合わせた有機相を、一定の重量に到達するまで、真空中で乾燥した。
実施例1aで得たベンダムスチンエチルエステル原料生成物を、210mlの32% HClに溶解し、40℃のジャケット温度で2時間撹拌した。この溶液を室温まで冷却し、8gの活性炭と混合し、30分間撹拌し、滅菌フィルターに通して濾過した。塩酸を蒸留によって分離し、残渣を400mlの水/アセトンと混合した。沈殿物を濾別し、水および酢酸エチルで洗浄し、乾燥した。
ベンダムスチンアルキルエステルの別の製造方法は、同様に、脱離生成物としてのエチル−4−(5−(ビス−(2−ヒドロキシエチル)アミノ)−1−メチル−1H−ベンゾ[d]イミダゾール−2−イル)アルキルエステルから出発する。この際、この脱離生成物の中のヒドロキシル基の脱離傾向(outgoing trend)は、活性化基(例えば、p−トシル基、メシル基またはトリフラート基)の付加によって増大される。次いで、ハロゲン化物によるこの活性化基の交換は、穏和な条件下で、例えばジメチルホルムアミドまたはエタノール中での塩化リチウムによる処理によって、可能である。
比較例2aで得たベンダムスチンエチルエステル原料生成物を、210mlの32% HClに溶解し、40℃のジャケット温度で2時間撹拌した。この溶液を室温まで冷却し、8gの活性炭と混合し、30分間撹拌し、滅菌フィルターに通して濾過した。塩酸を蒸留によって分離し、残渣を400mlの水/アセトンと混合した。沈殿物を濾別し、水および酢酸エチルで洗浄し、乾燥した。
ベンダムスチンエチルエステルを、独国特許第159877号明細書(特許文献2)の特定の実施例に従って生成した。この際、18.3molの塩化チオニル(2.175kg)を使用して、(4.305kgの4−[5−[ビス(2−ヒドロキシエチル)アミノ]−1−メチルベンゾイミダゾール−2−イル]ブタン酸エチルエステルの中の)22.3molのヒドロキシル基を置換した。しかしながら、これは、不完全な変換しか生じず、およそ47面積%の所望の生成物が反応混合物の中に得られたにすぎなかった。
Claims (18)
- 式(I)によって表される化合物
式(III)によって表される化合物
- Xは塩化物を表す、請求項1に記載の方法。
- R1およびR2は一緒に、式(II)によって表されるラジカルを表す、請求項1または請求項2に記載の方法。
- nは1〜3の範囲の整数である、請求項3に記載の方法。
- R4は、メチルラジカル、エチルラジカル、およびプロピルラジカルからなる群から選択されるアルキルラジカルを表す、請求項4に記載の方法。
- R4はメチルラジカルを表す、請求項5に記載の方法。
- R5は、メチルラジカル、エチルラジカル、プロピルラジカル、およびブチルラジカルからなる群から選択されるアルキルラジカルを表す、請求項1から請求項6のいずれか1項に記載の方法。
- R1はHであり、R2はCH2(CH2)mCOOHである、請求項1または請求項2に記載の方法。
- mは1〜3の範囲の整数である、請求項8に記載の方法。
- mは2に等しい、請求項9に記載の方法。
- 式(IV)によって表される化合物は、ジアルキルホルムアミドを含む、請求項1から請求項11のいずれか1項に記載の方法。
- 前記ジアルキルホルムアミドは、ジメチルホルムアミドを含む、請求項11に記載の方法。
- 式(IV)によって表される化合物は、ジメチルアセトアミドを含む、請求項1から請求項12のいずれか1項に記載の方法。
- 式(V)によって表される化合物は、ジメチルスルホキシドを含む、請求項1から請求項12のいずれか1項に記載の方法。
- 式(VI)によって表される化合物は、塩化オキサリルを含む、請求項1から請求項14のいずれか1項に記載の方法。
- 式(III)に係る化合物に対する式(VI)に係る化合物のモル比は少なくとも1.3に等しい、請求項1から請求項15のいずれか1項に記載の方法。
- 前記反応は、塩素化溶媒または非プロトン性溶媒の中で実施される、請求項1から請求項16のいずれか1項に記載の方法。
- 式(VII)によって表される化合物またはその塩の製造方法であって、
前記方法は請求項1に従って実施され、得られた式(I)によって表されるエステル化合物はエステル加水分解を受けることを特徴とする、方法。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201061426098P | 2010-12-22 | 2010-12-22 | |
DE102010055499A DE102010055499A1 (de) | 2010-12-22 | 2010-12-22 | Prozess zur Herstellung von Bendamustinalkylester, Bendarmustin sowie Derivaten davon |
US61/426,098 | 2010-12-22 | ||
DE102010055499.5 | 2010-12-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2012131790A true JP2012131790A (ja) | 2012-07-12 |
JP6014912B2 JP6014912B2 (ja) | 2016-10-26 |
Family
ID=43993097
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011273992A Active JP6014912B2 (ja) | 2010-12-22 | 2011-12-15 | ベンダムスチンアルキルエステル、ベンダムスチン、およびそれらの誘導体の製造のためのプロセス |
Country Status (14)
Country | Link |
---|---|
US (1) | US8481751B2 (ja) |
EP (1) | EP2468716B1 (ja) |
JP (1) | JP6014912B2 (ja) |
KR (2) | KR20120071339A (ja) |
CN (1) | CN102653525B (ja) |
AR (1) | AR084344A1 (ja) |
AU (1) | AU2011265491B2 (ja) |
BR (1) | BRPI1106854A2 (ja) |
CA (1) | CA2761399C (ja) |
DE (1) | DE102010055499A1 (ja) |
DK (1) | DK2468716T3 (ja) |
RU (1) | RU2505533C2 (ja) |
SG (1) | SG182090A1 (ja) |
TW (1) | TWI434835B (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015536996A (ja) * | 2012-11-12 | 2015-12-24 | イグニタ、インク. | ベンダムスチン誘導体およびこれを使用する方法 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9273010B2 (en) * | 2011-06-20 | 2016-03-01 | Hetero Research Foundation | Process for bendamustine hydrochloride |
DK2656843T3 (en) | 2012-04-26 | 2015-04-20 | Helmut Schickaneder | Esters of bendamustine and related compounds, and medical use thereof |
US8987469B2 (en) | 2012-07-24 | 2015-03-24 | Heyl Chemisch-Pharmazeutische Fabrik Gmbh & Co. Kg | Process for the preparation of bendamustine |
WO2023213445A1 (de) * | 2022-05-04 | 2023-11-09 | Heraeus Deutschland GmbH & Co. KG | Verfahren zur herstellung von 4-[5-[bis(2-chlorethyl)amino]-1-methyl-1h-benzo[d]imidazol-2-yl]butansäurealkylestern und formylierten derivaten |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DD34727A (ja) * | ||||
JPH093065A (ja) * | 1994-05-31 | 1997-01-07 | Mitsui Toatsu Chem Inc | ベンズイミダゾール誘導体 |
JPH09502199A (ja) * | 1993-09-09 | 1997-03-04 | メルク シヤープ エンド ドーム リミテツド | ドーパミン受容体サブタイプリガンドとしての縮合三環複素芳香族誘導体 |
JP2006523671A (ja) * | 2003-04-15 | 2006-10-19 | ファイザー・インク | PPAR調節剤としてのα置換カルボン酸 |
JP2007524595A (ja) * | 2003-02-28 | 2007-08-30 | レオジーン, インコーポレイテッド | エクジソン受容体複合体を通して外因性遺伝子の発現を調節するための生物学的利用能のあるジアシルヒドラジン・リガンド |
WO2008150379A1 (en) * | 2007-06-04 | 2008-12-11 | Polymed Therapeutics, Inc. | Novel chlorination process for preparing sucralose |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE34727C (de) | Ch. H. TH. HAVEMANN in Paris, 16 rue Bleue | Verfahren zur direkten Gewinnung metallischen Bleis | ||
DD34727A1 (de) | 1963-12-21 | 1964-12-28 | Dietrich Krebs | Verfahren zur Herstellung von 1-Stellung substituierten [5-Bis-(chloräthyl)-amino-benzimidazolyl-(2)]-alkancarbonsäuren |
DD159877A1 (de) | 1981-06-12 | 1983-04-13 | Wolfgang Krueger | Verfahren zur herstellung von 4-[1-methyl-5-bis(2-chloraethyl)amino-benzimidazolyl-2]-buttersaeure |
DE19824929A1 (de) * | 1998-06-04 | 1999-12-09 | Basf Ag | Verfahren zur Herstellung von Alkyl-, Alkenyl- und Alkinylchloriden |
IL149575A0 (en) * | 1999-12-08 | 2002-11-10 | Warner Lambert Co | Method for the stereoselective synthesis of cyclic amino acids |
-
2010
- 2010-12-22 DE DE102010055499A patent/DE102010055499A1/de not_active Ceased
-
2011
- 2011-12-08 CA CA2761399A patent/CA2761399C/en not_active Expired - Fee Related
- 2011-12-14 SG SG2011092525A patent/SG182090A1/en unknown
- 2011-12-15 JP JP2011273992A patent/JP6014912B2/ja active Active
- 2011-12-15 EP EP11009886.0A patent/EP2468716B1/de active Active
- 2011-12-15 DK DK11009886.0T patent/DK2468716T3/en active
- 2011-12-16 AR ARP110104751A patent/AR084344A1/es active IP Right Grant
- 2011-12-20 TW TW100147538A patent/TWI434835B/zh not_active IP Right Cessation
- 2011-12-21 KR KR1020110138828A patent/KR20120071339A/ko active Search and Examination
- 2011-12-21 RU RU2011152372/04A patent/RU2505533C2/ru active
- 2011-12-22 CN CN201110463150.2A patent/CN102653525B/zh active Active
- 2011-12-22 BR BRPI1106854-0A patent/BRPI1106854A2/pt not_active IP Right Cessation
- 2011-12-22 AU AU2011265491A patent/AU2011265491B2/en active Active
- 2011-12-22 US US13/334,402 patent/US8481751B2/en active Active
-
2014
- 2014-10-14 KR KR1020140138123A patent/KR20140128926A/ko active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DD34727A (ja) * | ||||
JPH09502199A (ja) * | 1993-09-09 | 1997-03-04 | メルク シヤープ エンド ドーム リミテツド | ドーパミン受容体サブタイプリガンドとしての縮合三環複素芳香族誘導体 |
JPH093065A (ja) * | 1994-05-31 | 1997-01-07 | Mitsui Toatsu Chem Inc | ベンズイミダゾール誘導体 |
JP2007524595A (ja) * | 2003-02-28 | 2007-08-30 | レオジーン, インコーポレイテッド | エクジソン受容体複合体を通して外因性遺伝子の発現を調節するための生物学的利用能のあるジアシルヒドラジン・リガンド |
JP2006523671A (ja) * | 2003-04-15 | 2006-10-19 | ファイザー・インク | PPAR調節剤としてのα置換カルボン酸 |
WO2008150379A1 (en) * | 2007-06-04 | 2008-12-11 | Polymed Therapeutics, Inc. | Novel chlorination process for preparing sucralose |
Non-Patent Citations (4)
Title |
---|
JPN6015021441; W. Werner, et al.: 'Synthesis of a potential metabolite of the anticancer drug bendamustine (Cytostasen)' Pharmazie Vol.46, No.2, 1991, pp.113-114 * |
JPN6015021443; W. Werner, et al.: 'Hydrolysis products of the antitumor drug Cytostasan (bendamustin)' Pharmazie Vol.42, No.4, 1987, pp.272-273 * |
JPN6015021445; R. Gust, et al.: 'Investigations on the stability of bendamustine, a cytostatic agent of the nitrogen mustard type. Pa' Monatshefte fuer Chemie Vol.128, No.3, 1997, pp.291-299 * |
JPN6015021447; Nobuo Kato, et al.: 'Synthetic photochemistry. XXXIV. Synthetic strategy of 5-8-5-membered tricyclic higher terpenoids ba' Bulletin of the Chemical Society of Japan Vol.59, No.4, 1986, pp.1109-1123 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015536996A (ja) * | 2012-11-12 | 2015-12-24 | イグニタ、インク. | ベンダムスチン誘導体およびこれを使用する方法 |
US9913827B2 (en) | 2012-11-12 | 2018-03-13 | Ignyta, Inc. | Bendamustine derivatives and methods of using same |
Also Published As
Publication number | Publication date |
---|---|
AU2011265491A1 (en) | 2012-07-12 |
EP2468716A1 (de) | 2012-06-27 |
JP6014912B2 (ja) | 2016-10-26 |
TW201302714A (zh) | 2013-01-16 |
TWI434835B (zh) | 2014-04-21 |
CA2761399C (en) | 2014-07-29 |
US8481751B2 (en) | 2013-07-09 |
CN102653525A (zh) | 2012-09-05 |
US20120165543A1 (en) | 2012-06-28 |
KR20120071339A (ko) | 2012-07-02 |
EP2468716B1 (de) | 2017-07-19 |
RU2505533C2 (ru) | 2014-01-27 |
BRPI1106854A2 (pt) | 2013-04-09 |
DK2468716T3 (en) | 2017-10-02 |
KR20140128926A (ko) | 2014-11-06 |
SG182090A1 (en) | 2012-07-30 |
AR084344A1 (es) | 2013-05-08 |
AU2011265491B2 (en) | 2013-02-07 |
CN102653525B (zh) | 2015-11-25 |
CA2761399A1 (en) | 2012-06-22 |
DE102010055499A1 (de) | 2011-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6014912B2 (ja) | ベンダムスチンアルキルエステル、ベンダムスチン、およびそれらの誘導体の製造のためのプロセス | |
CZ2016627A3 (cs) | Způsob přípravy (7-fenoxy-4-hydroxy-1-methylisochinolin-3-karbonyl)glycinu (roxadustatu) a jeho intermediátů založený na souběžném otevírání oxazolového kruhu, štěpení etheru a tvorbě iminu | |
JPS6327462A (ja) | O−置換ヒドロキシルアミンの製造法 | |
JP2010510253A5 (ja) | ||
KR101313842B1 (ko) | 에스-암로디핀 베실레이트 및 그 수화물의 제조방법 | |
RU2194706C2 (ru) | Способ получения дигидрохлорида 1-[[[5-(4-хлорфенил)-2-фуранил]метилен]амино]-3-[4-(4-метил-1-пиперазинил) бутил]-2,4-имидазолидиндиона | |
JP6891131B2 (ja) | エンザルタミドを調製するための新規な方法 | |
RU2425031C1 (ru) | Способ получения 3-замещенных 2-амино-1-гидрокси-5,6-дицианоиндолов на основе 4-бром-5-нитрофталонитрила | |
RU2194705C2 (ru) | Способ получения 1,3-дизамещенных 4-оксоциклических мочевин | |
JP2011519840A (ja) | 1,7’−ジメチル−2’−プロピル−2,5’−ビ−1h−ベンゾイミダゾールの製造 | |
JP2021080214A (ja) | ビオチンの製造方法 | |
JP2021526531A (ja) | リフィテグラストの製造方法 | |
EP1179532B1 (en) | Process for the production of indole derivatives and intermediates therefor | |
JP2002155058A (ja) | 1位置換ヒダントイン類の製造方法 | |
JP2005520805A5 (ja) | ||
US20070037854A1 (en) | Process for preparing sulfonamide-containing indole compounds | |
JP2015518014A (ja) | アミノ酸のデーン塩を使用することによるジアミドゲル化剤の合成 | |
JP5164755B2 (ja) | ビス−アセチルアミノフェニル化合物の結晶の製造方法 | |
KR20160060188A (ko) | 솔리페나신 또는 그 염의 결정형 제조방법, 이에 사용되는 신규 중간체 및 그 제조방법 | |
JPS63211280A (ja) | 2−(4−チアゾリル)ベンツイミダゾ−ルの製造法 | |
JP5649170B2 (ja) | テトラヒドロ−β−カルボリン誘導体及びその製造方法 | |
KR101213467B1 (ko) | 로자탄 대사체 이엑스피-3174 이수화물의 신규한 제조 방법 | |
JP2008273841A (ja) | エチレンジアミン誘導体及びその製造法 | |
JPS61158962A (ja) | 1,4−ジヒドロピリジン誘導体の製造法 | |
JP2005112807A (ja) | アミノアルコキシカルボスチリル誘導体の製造方法。 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20131227 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140930 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150602 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20150604 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150902 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160223 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160329 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160816 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20160906 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160906 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6014912 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |